Posted by MarketBeat News on Dec 26th, 2024
StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research note published on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Separately,...
More of this article »